Clinical Oncology Next Generation Sequencing Market Forecast: How Big Will It Be by 2030?
Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company
Starting from its 2026 valuation, what market size is the Clinical Oncology Next Generation Sequencing Market expected to reach by 2030?
The clinical oncology next generation sequencing market has seen substantial growth recently. It is projected to expand from $0.58 billion in 2025 to $0.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.3%. The historical increase in market size is due to several factors, including the widening of cancer genomics research, greater availability of sequencing platforms, an increase in oncology clinical trials, the rising acceptance of molecular diagnostics, and a reduction in sequencing expenses.
The clinical oncology next generation sequencing market is anticipated to experience rapid growth over the next few years. It is projected to expand to $1.04 billion by 2030, with a compound annual growth rate (CAGR) of 12.1%. The drivers for this growth in the forecast period include increasing demand for precision oncology, rising investments in genomic medicine, the expansion of hospital-based sequencing laboratories, a growing use of targeted cancer therapies, and continuous advancements in sequencing technologies. Significant trends for the forecast period comprise the increasing adoption of NGS-based oncology diagnostics, rising use of companion diagnostic applications, the growing integration of bioinformatics and data analytics, the expansion of personalized cancer treatment approaches, and an enhanced focus on rare mutation detection.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp
What Drivers Are Driving Adoption Within The Clinical Oncology Next Generation Sequencing Market?
The increasing incidence of cancer is anticipated to drive the expansion of the clinical oncology next-generation sequencing market in the coming period. Cancer refers to a collection of illnesses marked by the unregulated proliferation and dissemination of atypical cells throughout the body. This growing prevalence is primarily attributed to an aging population, given that the risk of developing cancer substantially rises with advancing age. NGS serves to detect novel and uncommon mutations in cancer, thereby offering a more profound insight into the molecular foundations of specific tumors. For example, data from February 2024, published by the World Health Organization, a Switzerland-based public health agency of United Nations, indicates a projection of over 35 million new cancer cases by 2050. This represents a 77% increase relative to the approximately 20 million cases reported in 2022. Consequently, the increasing occurrence of cancer is a key factor boosting the expansion of the clinical oncology next-generation sequencing market.
What Segments Are Included Within The Clinical Oncology Next Generation Sequencing Market?
The clinical oncology next generation sequencing market covered in this report is segmented –
1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing
2) By Application: Screening, Companion Diagnostics, Other Diagnostics
3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories
Subsegments:
1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies
2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies
3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies
4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies
5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies
6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies
7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies
Which Trends Are Expected To Influence The Clinical Oncology Next Generation Sequencing Market In The Upcoming Years?
Leading companies operating within the clinical oncology next-generation sequencing (NGS) market are prioritizing advancements in technology, particularly by integrating software accelerators that substantially decrease the time and expenditure associated with second-level NGS analysis. This innovation allows laboratories to provide results more rapidly while also diminishing computational resource requirements. These advanced accelerator technologies facilitate comprehensive genomic profiling and enhance the accessibility of high-throughput cancer panels for both major centralized laboratories and decentralized diagnostic environments. As an illustration, in January 2024, QIAGEN Digital Insights, a bioinformatics company based in Germany, unveiled an improved iteration of its CLC Genomics Workbench Premium, which now incorporates LightSpeed technology to support somatic cancer secondary analysis. The LightSpeed accelerator is capable of analyzing a 275-gene cancer panel at 3377× coverage in merely 6 minutes, incurring a cost of less than US$ 0.72 per test in standard cloud setups. Furthermore, LightSpeed is optimized to ensure high speed, accuracy, reduced power consumption, and requires no new hardware or additional licenses beyond the existing CLC platform.
Who Are The Prominent Global Companies Shaping The Clinical Oncology Next Generation Sequencing Market Landscape?
Major companies operating in the clinical oncology next generation sequencing market are Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.
Access The Complete Report For Deeper Market Insights:
Which Geographic Areas Are Emerging As Strong Markets For The Clinical Oncology Next Generation Sequencing Market?
North America was the largest region in the clinical oncology next-generation sequencing market in 2025. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Clinical Oncology Next Generation Sequencing Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3344&type=smp
Browse Through More Reports Similar to the Global Clinical Oncology Next Generation Sequencing Market 2026, By The Business Research Company
Clinical Chemistry Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-chemistry-global-market-report
Dental Diagnostic Imaging Devices And Equipment Global Market Report 2026
Biochemistry Analyzer Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/biochemistry-analyzer-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
